The FDA Oncologic Drugs Advisory Committee recommended against approval of the Novartis agent Farydak (panobinostat), a pan-deacetylase inhibitor, for the indication of previously treated multiple myeloma when used in combination with bortezomib and dexamethasone.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
